Key Facts:
Important Information / Disclaimer
Exomind™ is included on the Australian Register of Therapeutic Goods (ARTG ID 481085).
Always read the label and follow the directions for use.
This product is intended for use by qualified healthcare professionals only.
Consult a healthcare professional to determine if this treatment is appropriate for your needs.
Patient experience and results may vary.
Reference:
Dees M., Halaas Y., McCoy J.D. ExoTMS™ Technology: A Novel Breakthrough in Transcranial Magnetic Stimulation for Enhancing Mental Well-Being. Journal of Psychiatry and Psychiatric Disorders. 2025; 9(3): 245–254.
BTL has introduced Exomind™, a non-invasive medical device powered by ExoTMS™ technology. Designed for use by qualified health professionals, the system delivers precisely controlled electromagnetic pulses to specific brain regions linked to mood regulation and cognitive function.
How Exomind™ is Used
During a session, the patient is seated comfortably while the device is positioned above the head. The procedure is non-invasive, requires no anaesthesia, and sessions last around 25 minutes. Treatment programs typically involve 4–6 sessions over 1–2 months, always delivered under professional supervision.
Patient-Reported Experiences
In clinical settings, some patients describe feeling calmer, more focused, and experiencing improved mood regulation. These are patient-reported experiences, and results vary. Treatments are provided by trained health professionals who assess each case individually.
Emerging Research
Recent peer-reviewed research has investigated ExoTMS™ in relation to mental well-being, reporting improvements across validated measures of mood and daily function (Dees et al., 2025). These findings are preliminary; results may vary, and treatment must always be delivered under professional supervision.
Quote:
"Exomind™ offers health professionals a highly adaptable, non-invasive tool to support their treatment programs," said Gareth Pepper, Director ANZ, BTL Aesthetics. "Its simplicity and flexibility make it well-suited to a variety of clinical environments."
About ExoTMS™
ExoTMS™ is a targeted electromagnetic stimulation technology that delivers precisely controlled pulses to specific brain regions linked to mood regulation and cognitive processes. Research has explored how TMS may stimulate regions such as the dorsolateral prefrontal cortex (DLPFC) and modulate connectivity as part of neural pathways involved in emotional processing. These findings are preliminary and are presented as research outcomes, not guaranteed effects.
Professional-Only Availability
Exomind™ is a regulated medical device and must be used under the direction of qualified healthcare practitioners. It is not available for purchase by the general public.
More: btlaesthetics.com.au
About us:
Founded in 1993, BTL develops medical and aesthetic technologies used across professional clinic settings worldwide. In Australia and New Zealand, the BTL portfolio includes EMFACE®, EMSCULPT NEO®, EMSCULPT®, EMSELLA®, EXION™, EXILIS ULTRA 360®, and EMFUSION™ (cosmetic aesthetic technology). All BTL systems are available for use by trained professionals in clinic environments.
